| Just Announced!
Galmed Pharmaceuticals (Nasdaq: GLMD) is Our Next Potential Breakout Idea For Monday Morning—3/17/2025.
Here’s Why…
Ultra Low Float: There’s Less Than 1.65M Shares Listed In The Public Float For (GLMD) — Which Could Lead To The Potential For Significant Swings If Demand Begins To Shift.
Technical Indicators: According To Technical Indicators, (GLMD) Appears To Be Entering An Oversold Territory — Which Could Suggest The Potential For A Trend Reversal.
Analyst Coverage: Just A Few Days Ago, On Friday 3/14/2025, Maxim Group Published A Report With A $12 Target On (GLMD) — Which Suggests An Upside Potential Of Over 597% From Its $1.72 Close.
Consider Adding Galmed Pharmaceuticals (NASDAQ: GLMD) To Your Radar This Morning…
March 17, 2025
Dear Reader,
Are you watching this?
Galmed Pharmaceuticals (Nasdaq: GLMD) reached $2.40 this morning, marking an approximate 39% move from Friday’s $1.72 close.
This showcased the potential for technical momentum as (GLMD) surpassed several key moving averages including: 5-Day: 1.7805 20-Day: 2.1752
With its 50-Day moving average at 2.5733, 100-Day at 2.8796, and 200-Day at 3.5727, we’re keeping a very close eye on (GLMD) right now.
In fact, this isn’t the first time we covered Galmed Pharmaceuticals (Nasdaq: GLMD).
The last time we brought you (GLMD) it moved approximately 182% in less than 24 hours.
And since our last two “Sunday Night Profiles” have moved a combined 175% (approx.), we have a very good feeling you’ll be keeping an eye on (GLMD) this morning.
You see, biotech and pharma are some of the most exciting industries, where a single breakthrough can turn an under-the-radar company into a major market player overnight.
Galmed Pharmaceuticals (NASDAQ: GLMD) is a clinical-stage biopharmaceutical company focused on liver, metabolic, and fibro-inflammatory diseases.
The company is advancing Aramchol Meglumine, a potential treatment for Primary Sclerosing Cholangitis (PSC) and other fibrotic conditions.
Aramchol, in Phase 3 clinical development, has already demonstrated significant fibrosis improvement in patients with NASH and fibrosis, as published in Hepatology.
As the most advanced SCD-1 downregulator in clinical trials, Aramchol continues to show potential in multiple therapeutic areas. Learn more here.
On Friday, 3/14/2025, Maxim Group published a report which listed Galmed Pharmaceuticals (Nasdaq: GLMD) with a $12 target, which suggests an upside potential of over 597% from its $1.72 close.
3 Reasons Why We Will Have All Eyes on Galmed Pharmaceuticals (Nasdaq: GLMD) This Morning…
1. Ultra Low Float: There’s less than 1.65M shares listed in the public float for (GLMD). This limited float could lead to the potential for significant swings if demand begins to shift.
2. Technical Indicators: According to technical indicators found on Barchart, (GLMD) appears to be entering an oversold territory, which could suggest the potential for a trend reversal.
3. Analyst Coverage: Just a few days, on Friday 3/14/2025, Maxim Group published a report with a $12 target on (GLMD), which suggests an upside potential of over 597% from its $1.72 close.
Consider Adding Galmed Pharmaceuticals (Nasdaq: GLMD) to Your Radar Today…
When a profile like this starts catching momentum, things can move fast—we’ve seen it happen before.
We have all eyes on (GLMD) this morning.
Consider taking a look at (GLMD) while it’s still early.
Don’t forget, the last time we covered (GLMD), it moved approximately 182% in less than 24 hours. Last thing, keep an eye out for my next update—it could be coming your way very shortly. | 
No comments:
Post a Comment